Health Canada approves the use of remdesivir, a drug intended to treat patients with severe symptoms of COVID-19, subject to conditions.
It is the first drug of its kind to receive the green light from the competent authorities. It is allowed in adults and adolescents (aged 12 years or older and weighing at least 40 kg).
Health Canada conditions its use on the condition that the manufacturer, Gilead Sciences Canada, continues to ensure its safety, efficacy and quality , as stated in a press release from the federal agency.
Remdesivir is administered intravenously and will only be used in care facilities where patients can be closely monitored , the same statement said.
Health Canada says it will continue to closely monitor the safety of remdesivir in Canada and will respond quickly to safety concerns .
